Interpretable machine learning model for early complication prediction after split liver transplantation

Figure 5 Comparison of alanine aminotransferase and aspartate aminotransferase levels (U/L) in recipients at 1 day and 7 days post-transplant. A: Significantly higher alanine aminotransferase levels without partial lobectomy of segment IV vs partial lobectomy of segment IV at 1 day (P < 0.05); B: No significant difference in aspartate aminotransferase levels between without partial lobectomy of segment IV and partial lobectomy of segment IV; C: Significantly higher alanine aminotransferase levels in the high model for end-stage liver disease group compared to the low model for end-stage liver disease group at 1 day (P < 0.05); D: Significantly higher aspartate aminotransferase levels in the high model for end-stage liver disease group at 1 day (P < 0.05), with no significant differences observed at 7 days. IV WPL: Without partial lobectomy of segment IV; IV PL: Partial lobectomy of segment IV; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NS: Not significant; MELD: Model for end-stage liver disease.